J0583 HCPCS Level II code: Injection, bivalirudin, 1 mg
J0583 is the HCPCS code for “Injection, bivalirudin, 1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J0583Injection, bivalirudin, 1 mg
Short description: Bivalirudin
HCPCS · United States
Medicare details
The indicators CMS publishes with J0583 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2004
Where J0583 sits
- 1J codesDrugs administered other than orally
- 2Active code J0583Injection, bivalirudin, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J0583 mean?
J0583 is the HCPCS code for “Injection, bivalirudin, 1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J0583?
CMS lists J0583’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J0583
All J codesJ0574Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphineJ0575Buprenorphine/naloxone, oral, greater than 10 mg buprenorphineJ0576Injection, buprenorphine extended-release (brixadi), 1 mgJ0577Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapyJ0578Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapyJ0582Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mgJ0584Injection, burosumab-twza 1 mgJ0585Injection, onabotulinumtoxina, 1 unitJ0586Injection, abobotulinumtoxina, 5 unitsJ0587Injection, rimabotulinumtoxinb, 100 unitsJ0588Injection, incobotulinumtoxin a, 1 unitJ0589Injection, daxibotulinumtoxina-lanm, 1 unit